🔎 Trials Near Me

Hjem › Kronisk lymfatisk leukemi › Washington › Seattle

Kliniske studier for Kronisk lymfatisk leukemi i Seattle, WA

20 studier for Kronisk lymfatisk leukemi søker deltakere på steder i og rundt Seattle (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
  • Swedish Medical Center-Ballard Campus, Seattle
  • Swedish Medical Center-Cherry Hill, Seattle
  • Swedish Medical Center-First Hill, Seattle
  • og 1 flere
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

RekruttererFase 1/2
  • Research Site, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

RekruttererFase 3
  • Fred Hutchinson Cancer Center, Seattle
  • Swedish Medical Center-First Hill, Seattle
  • FHCC at Northwest Hospital, Seattle
  • og 1 flere
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT04269902

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

RekruttererFase 1/2
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

RekruttererFase 3
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07277231

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

RekruttererFase 1/2
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06697184

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

RekruttererFase 3
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT06973187

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

RekruttererFase 3
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

RekruttererFase 2
  • Fred Hutchinson Cancer Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 17. sep. 2026 · NCT07221500

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT07194980

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

RekruttererFase 1
  • Fred Hutch Cancer Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT06528301

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

RekruttererFase 2Frivillige helsepersonell ønskes velkommen
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Alle kjønn · Oppdatert 29. mai 2026 · NCT04195633

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 18. mai 2026 · NCT04941716

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 22. apr. 2026 · NCT06839053

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

RekruttererFase 4
  • Swedish Cancer Institute, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

RekruttererFase 4
  • Swedish Cancer Institute, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 2. mar. 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

RekruttererFase 1
  • Fred Hutchinson Cancer Center, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 13. feb. 2026 · NCT05544019

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

RekruttererFase 2
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Alder 18 til 80 · Alle kjønn · Oppdatert 14. okt. 2025 · NCT06520098

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

RekruttererFase 1
  • Swedish Cancer Institute, Seattle
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2025 · NCT05780034

Kronisk lymfatisk leukemi-studier i andre byer

Andre studier i Seattle

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.